The genus *Acinetobacter* comprises to date more than 50 species, among which *Acinetobacter baumannii* is the most clinically relevant, often associated with pneumonia, septicaemia, urinary tract infections, wound infections and meningitis [@bib1]. Treatment of infections caused by this opportunistic bacterium is a challenge as a result of its strong ability to develop resistance to a wide range of antimicrobial agents, especially carbapenems. This resistance trait is mainly related to production of acquired carbapenem-hydrolyzing class D β-lactamases and metallo-β-lactamases [@bib2]. In the last decades, the role of non-*baumannii Acinetobacter* in human infections has been increasingly recognized as a result of advances in molecular biology [@bib3]. There are several reports of multidrug-resistant strains of *Acinetobacter pittii* and *Acinetobacter nosocomialis* in healthcare facilities around the world [@bib4].

This study was initiated by the isolation of two imipenem-resistant *A. pittii* strains recovered in two hospitals in Tripoli, North Lebanon, in 2015. The first one, designated CMUL332, was isolated from the urine of a 4-month-old child who was admitted to the intensive care unit for fever and nephritic syndrome. The second one, CMUL334, was isolated from the urine of a 15-year-old girl patient hospitalized with febrile gastroenteritis. Bacterial identification was performed by matrix-assisted desorption ionization--time of flight mass spectrometry and partial *rpo*B gene sequencing [@bib5]. Antimicrobial susceptibility was determined by the disk diffusion method according to the recommendations of the European Committee on Antimicrobial Susceptibility Testing (<http://www.eucast.org>). Both isolates were resistant to ticarcillin, ticarcillin/clavulanate and ceftazidime and were of intermediate susceptibility to piperacillin/tazobactam. In contrast, they remained susceptible to aminosides, tigecycline, rifampin, ciprofloxacin and colistin, except strain CMUL332, which was resistant to tobramycin and netilmicin. The Etest method confirmed the carbapenem-resistant phenotype because the minimum inhibitory concentration for meropenem was \>32 mg/L and for imipenem either \>32 mg/L (CMUL332) or 16 mg/L (CMUL334). Screening of *bla*~OXA-23-like~, *bla*~OXA-24-like~, *bla*~OXA-58-like~ and *bla*~NDM~ genes by real-time PCR revealed that CMUL332 harboured the *bla*~NDM~ gene, while CMUL334 carried the *bla*~OXA-24\ like~ gene. Sequencing of the entire carbapanemase genes showed that they encoded for NDM-1 and OXA-72 variants, respectively.

OXA-72-producing *A. pittii* was first described in Colombia in 2012 from a catheter tip--positive culture of a patient who had ischaemic hepatitis and multiorgan failure [@bib6]. This enzyme has subsequently been reported from carbapenem-resistant clinical isolates of *A. pittii* in France [@bib7]. On the other hand, identification of NDM-positive non-*baumannii Acinetobacter* is now increasingly reported worldwide, concomitantly with those of *A. baumannii* isolates. Indeed, recent studies have demonstrated the emergence and the dissemination of NDM-1-producing *A. pittii* in several countries, including China [@bib4], [@bib8], Turkey [@bib9] and recently Brazil [@bib10].

This study is the first report of *A. pittii* producing OXA-72 and NDM-1 in Lebanon, which highlights the clinical relevance of this bacterium, in accordance with a series of recent studies [@bib3]. Therefore, surveillance is warranted, and early detection of carbapenemase genes is recommended to avoid their major spread to more clinically relevant bacterial species.
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